| Literature DB >> 35223463 |
Chuansheng Nie1, Youfan Ye2, Jingnan Wu1, Hongyang Zhao1, Xiaobing Jiang1, Haijun Wang1.
Abstract
OBJECTIVE: Craniopharyngioma has always been a challenge for the neurosurgeon, and there is no consensus on optimal treatment. The objective of this study was to compare surgical outcomes and complications between transcranial surgery (TCS) and endoscopic endonasal surgery (EES) of craniopharyngiomas.Entities:
Keywords: craniopharyngiomas; endoscopic; outcomes; surgery; transcranial surgery
Year: 2022 PMID: 35223463 PMCID: PMC8866852 DOI: 10.3389/fonc.2022.755342
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Patient presented with visual deficit, pituitary and elevated intracranial pressure syndromes. Preoperative MRI (A–D) illustrated a giant intra-suprasellar craniopharyngioma. Postoperative MRI (E–H) confirmed gross total resection.
Figure 2(A) The tumor broke through the sphenoid sinus and grew to the nasal cavity. (B, C) An extended transnasal approach was performed. (D) Decompression inside the tumor. (E) Removal of the saddle septum attached to the base of the tumor. (F–H) Remove the adhesion tissue between the tumor and the cavernous sinus and internal carotid artery. (I) Pituitary stalk was preserved. (J–L) Tumor was gross total removed.
Main clinical manifestations of all the patients.
| Variable | All cases | EES (%) | TCS (%) | p value |
|---|---|---|---|---|
| No. of cases | 273 | 88 (32.2) | 185 (67.8) | |
| Mean age (SD) | 38.1 (12.9) | 37.8 (13.8) | 38.2 (12.3) | 0.37 |
| Male sex | 128 | 41 (46.6) | 87 (47.0) | 1.00 |
| Symptoms | ||||
| Headache | 202 | 71 (80.7) | 131 (70.8) | 0.10 |
| Impaired cognition | 24 | 9 (10.2) | 15 (8.1) | 0.65 |
| Visual deficits | 134 | 47 (53.4) | 87 (47.0) | 0.37 |
| Obesity | 22 | 8 (9.1) | 14 (7.6) | 0.64 |
| Hydrocephalus | 39 | 11 (12.5) | 28 (15.1) | 0.71 |
| Endocrine deficiencies | 132 | 33 (37.5) | 75 (40.5) | 0.69 |
EES, endoscopic endonasal surgery; TCS, transcranial surgery.
Tumor size, histopathological subtype, and consistency.
| All cases | EES (%) | TCS (%) | p value | |
|---|---|---|---|---|
| No. of cases | 273 | 88 (32.2) | 185 (67.8) | |
| Mean tumor vol in cm3 (SD) | 8.2 (7.9) | 7.5 (8.4) | 8.7 (7.1) | 0.48 |
| Tumor consistency | ||||
| Cystic | 80 (29.3) | 23 (26.1) | 57 (30.8) | 0.48 |
| Solid | 59 (21.6) | 18 (20.5) | 41 (22.1) | 0.88 |
| Mixed | 134 (49.1) | 47 (53.4) | 87 (47.1) | 0.37 |
| Pathological type | ||||
| Adamantinomas | 247 (90.5) | 77 (87.5) | 170 (91.9) | 0.27 |
| Papillary | 26 (9.5) | 11 (12.5) | 15 (8.1) | 0.27 |
EES, endoscopic endonasal surgery; TCS, transcranial surgery.
Main postoperative and perioperative complications.
| Complications | All cases | EES (%) | TCS (%) | p value |
|---|---|---|---|---|
| No. of cases | 273 | 88 | 185 | |
| Hypopituitarism | 173 | 47 | 126 | 0.02 |
| Diabetes insipidus | 179 | 45 | 134 | <0.01 |
| CSF leaks | 4 | 4 | 0 | 0.01 |
| Wound infection | 10 | 2 | 8 | 0.51 |
| Meningitis | 6 | 2 | 4 | 1.00 |
| Hemorrhage | 5 | 2 | 3 | 1.00 |
| Seizures | 5 | 1 | 4 | 0.67 |
| Death | 0 | 0 | 0 | 1.00 |
CSF, cerebrospinal fluid; EES, endoscopic endonasal surgery; TCS, transcranial surgery.